×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CPRX – catalyst pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CPRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/16
02:51 am
cprx
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]
Low
Report
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]
3/15
10:29 pm
cprx
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]
Low
Report
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]
3/14
03:29 pm
cprx
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]
3/12
02:45 am
cprx
Full Year 2025 Trading Update [Yahoo! Finance]
Medium
Report
Full Year 2025 Trading Update [Yahoo! Finance]
3/10
05:42 pm
cprx
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
11:06 am
cprx
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount [Yahoo! Finance]
3/9
02:25 am
cprx
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy [Yahoo! Finance]
3/6
08:25 am
cprx
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
04:07 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
0.1%
catalyst pharmaceuticals, inc.
11/5/2025
04:06 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-6.8%
catalyst pharmaceuticals, inc.
8/6/2025
04:13 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-9.8%
catalyst pharmaceuticals, inc.
5/7/2025
04:14 pm
cprx
catalyst pharmaceuticals, inc.
BEAT
Report
-6.2%
catalyst pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
3/19
06:02 am
cprx
Form 8-K/A CATALYST PHARMACEUTICALS For: Mar 18
Medium
Report
Form 8-K/A CATALYST PHARMACEUTICALS For: Mar 18
3/18
05:15 pm
cprx
Form 8-K CATALYST PHARMACEUTICALS For: Mar 18
Low
Report
Form 8-K CATALYST PHARMACEUTICALS For: Mar 18
2/25
04:23 pm
cprx
Form 8-K CATALYST PHARMACEUTICALS For: Feb 25
Low
Report
Form 8-K CATALYST PHARMACEUTICALS For: Feb 25
2/25
04:07 pm
cprx
Form 10-K CATALYST PHARMACEUTICALS For: Dec 31
Medium
Report
Form 10-K CATALYST PHARMACEUTICALS For: Dec 31
2/19
05:04 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Feb 17 Filed by: Russo Gregg
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Feb 17 Filed by: Russo Gregg
1/12
08:03 am
cprx
Form 8-K CATALYST PHARMACEUTICALS For: Jan 12
Low
Report
Form 8-K CATALYST PHARMACEUTICALS For: Jan 12
1/6
05:01 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Kalb Michael Wayne
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Kalb Michael Wayne
1/6
05:00 pm
cprx
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Daly Richard J
Low
Report
Form 4 CATALYST PHARMACEUTICALS For: Jan 05 Filed by: Daly Richard J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/9
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
15.9%
5/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 12.7%
4/8 Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities 11.5%
1/6 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs 11.1%
3/10 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020 9.8%
2/5 Form 8-K CATALYST PHARMACEUTICALS For: Feb 04 9.5%
3/16 Q4/2019 12/31/2019 EPS 0.070 ZacksConsensus 0.090 ActVsEst (0.020) - Miss 8.6%
6/12 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration 7.9%
11/13 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) had its price target lowered by analysts at Piper Jaffray Companies from $8.00 to $7.00. 5.6%
9/24 Form 8-K CATALYST PHARMACEUTICALS For: Sep 23 5.5%
5/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 12.7%
4/8 Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities 11.5%
1/6 Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs 11.1%
3/10 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020 9.8%
2/5 Form 8-K CATALYST PHARMACEUTICALS For: Feb 04 9.5%
3/16 Q4/2019 12/31/2019 EPS 0.070 ZacksConsensus 0.090 ActVsEst (0.020) - Miss 8.6%
6/12 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration 7.9%
11/13 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) had its price target lowered by analysts at Piper Jaffray Companies from $8.00 to $7.00. 5.6%
9/24 Form 8-K CATALYST PHARMACEUTICALS For: Sep 23 5.5%
TOP News Decliners
3/15
Catalyst Pharmaceuticals Q4 2019 Earnings Preview [Seeking Alpha]
-23.2%
9/11 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock -14.9%
10/30 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS) -14.5%
4/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
5/13 Form 8-K CATALYST PHARMACEUTICALS For: May 13 -11.7%
8/7 Q2/2019 6/30/2019 EPS 0.100 ZacksConsensus 0.030 ActVsEst 0.070 - Beat -10.7%
2/27 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020 -10.3%
12/20 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.9%
9/13 Form 8-K CATALYST PHARMACEUTICALS For: Sep 13 -8.0%
11/12 Form 10-Q CATALYST PHARMACEUTICALS For: Sep 30 -7.3%
9/11 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock -14.9%
10/30 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS) -14.5%
4/14 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
5/13 Form 8-K CATALYST PHARMACEUTICALS For: May 13 -11.7%
8/7 Q2/2019 6/30/2019 EPS 0.100 ZacksConsensus 0.030 ActVsEst 0.070 - Beat -10.7%
2/27 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020 -10.3%
12/20 Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.9%
9/13 Form 8-K CATALYST PHARMACEUTICALS For: Sep 13 -8.0%
11/12 Form 10-Q CATALYST PHARMACEUTICALS For: Sep 30 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: